Advancing knowledge of the immunoglobulins and their subgroups is setting the stage for more selective use of gamma globulin preparations. Crucial to appropriate therapy, Dr. Miller says, is accurate information on whether an immunoglobulin deficiency actually exists in a particular patient, a judgment that requires both a truly quantitative assay and an evaluation of laboratory results on an age-adjusted basis.